Opioid Addiction: Why Don’t More Rehabs Use Suboxone?

Is it true that taking Suboxone will make you gain weight?
Rehab Helps Thousands of Addicts Quit. Who Answers?

People frequently seek my help in finding an addiction treatment facility for themselves or a loved one. And just recently, a family sought my assistance in locating residential treatment for their opioid-addicted young adult son.

One facility after another told me they don’t use or recommend “maintenance” use of buprenorphine – a medication most people know as Suboxone – aside from using it during detox to make withdrawal a more “comfortable” experience.

Suboxone is a combination of buprenorphine and naloxone, a medication added to decrease the potential for misuse. Many research studies show that maintenance or long-term use of Suboxone (or methadone) not only helps individuals remain free from addiction to opioids like prescription painkillers and heroin, it lowers death rates and prevents addiction-related complications like infection.

The National Institute on Drug Abuse provides background information on these medications and how they work, as does the Substance Abuse and Mental Health Administration (SAMHSA).

What Do Addiction Treatment Centers Think of Suboxone?

I recently queried several rehab facilities to ask whether they use or recommend Suboxone past the detox phase of treatment.

Here are some of the responses I received from representatives of those facilities:

  • “Short answer, no. Suboxone is a temporary solution for a permanent problem.”
  • “You can get strung out on Suboxone as badly as on heroin.”
  • “Oh no, absolutely not. We do not discharge them on Suboxone.” (Coincidentally, when I mentioned that the scientific literature indicates people do better on maintenance Suboxone than not, I was told, “The scientific literature is false. I’ve been doing this for 20 years.”
  • “We’re abstinence-based. Our success is getting to the underlying issues. We can’t get to those when they’re under the influence of a narcotic medication.”

Technically, Suboxone and methadone are opioid medications, and opioids are sometimes called narcotics. Both block cravings and drug seeking, but do not produce a high or impair functioning when properly prescribed and taken as directed. In fact, if someone treated with Suboxone uses an opioid such as heroin, the euphoric effects are usually dampened or suppressed.

“The notion that these are ‘narcotics’ that prevent people from doing intensive therapy when used properly is ridiculous; the converse is true.” says Mark Willenbring, M.D., founder and CEO of Alltyr treatment clinic and former Director of the Division of Treatment and Recovery Research of the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health (NIH). In fact, to achieve stable recovery, many people need to stay on these medications for long periods of time – sometimes indefinitely.

Another less commonly used medication for maintenance treatment is naltrexone, available in pill form or as an extended-release monthly injection marketed as Vivitrol. Naltrexone blocks the opioid receptors and completely prevents the effect of opioid drugs like heroin or prescription opioids.

One-on-One With Suboxone Advocate Dr. Andrew Saxon

Why the resistance to Suboxone? I posed this question (and many more) to the University of Washington’s Andrew J. Saxon, M.D., an addiction psychiatrist with decades of clinical, research, and educational experience in opioid use disorders.

When I told him about my difficulties trying to find a rehab that supported Suboxone maintenance treatment, he said, “I get so frustrated with these inpatient programs that are wasting people’s time and money and exposing them to risk of overdose.”

Saxon was referring to the fact that patients who get discharged without being placed on Suboxone or referred to Suboxone prescribers are highly likely to experience drug cravings and relapse. They also risk overdose; if patients return to pre-treatment levels of drug use after being abstinent in rehab, their bodies won’t be able to handle such high drug levels.
 
Following are Dr. Saxon’s responses to my questions about the resistance to maintenance use of Suboxone:
 
Anne Fletcher: Why do you think so many treatment providers continue to be resistant to Suboxone (and methadone) maintenance treatment for opioid use disorders?

Dr. Andrew Saxon: Of course it is only speculation, but one obvious answer is that residential and inpatient programs have a financial incentive to detox people and tell them that recovery without medication-assisted treatment is better. If a patient is choosing to go on methadone or Suboxone, inpatient treatment is unnecessary in the vast majority of cases. Also, many of the staff in these programs are recovering from alcohol use disorders (AUDs). They simply do not understand that opioid use disorders (OUDs) are substantially different, though of course there are some commonalities.

Another reason for resistance is fear of Suboxone “diversion,” something that occurs when the medication is abused, not used as prescribed, or given/sold to other people. Studies suggest that most diversion occurs when people who are addicted to opioids try to get off them and don’t have medical access to Suboxone. It is very rare in the U.S. for people to use Suboxone in an attempt to get high.
 
Anne: How are OUDs substantially different than AUDs?

Dr. Saxon: Opioids affect the brain and the body differently than alcohol. So the substance effects, the intoxication, the withdrawal, and the ultimate long-term changes that occur after years of exposure are bound to be different. Fully explicating the differences on a cellular or molecular level is probably a Nobel Prize-winning endeavor! But it all means that treatment needs for OUDs are not the same as for AUDs.
 
Anne: Is there any evidence that residential treatment is valuable for OUDs?

Dr. Saxon: There is no evidence that I know of for the standard 28-day programs, but we do know the risk of overdose is high after leaving one of those programs if patients are not continued on Suboxone or methadone. There is evidence for therapeutic communities, residential facilities where patients stay six months or longer. Of course, such programs are few and far between.
 
Anne: The CEO (and addiction psychiatrist) of a company that owns several prominent rehabs directed me to a large Australian study, pointing out that one-year outcomes showed medication maintenance treatment and residential treatment were equally effective. Why do we seldom hear about this study?

Dr. Saxon: One cannot generalize from Australia to the U.S. – they have a very different healthcare system than we do. Also, there were multiple problems with the study design. For instance, it was not randomized; the researchers didn’t even report if there were baseline differences between the groups. Additionally, all outcome data were based totally on self-report, so we have no objective findings.
 
Anne: It’s often stressed that whenever maintenance medications are prescribed for OUDs, counseling is also important. But haven’t a number of recent studies shown that counseling confers no added benefit to the medication alone?

Dr. Saxon: Such studies relate specifically to office-based treatment with Suboxone and not to methadone maintenance. The findings are consistent in showing that outcomes were not improved when either drug counseling or cognitive-behavioral therapy were added to the use of Suboxone and medical management alone. So in early treatment, it is the medication (Suboxone) causing most change.

The findings are consistent in showing that outcomes were not improved when either drug counseling or cognitive-behavioral therapy were added to the use of Suboxone and medical management alone.-Dr. Andrew Saxon

Keep in mind that these studies only look at patients in the first several months of treatment, so we really don’t know the effects of behavioral interventions later on.

Moreover, it’s important to realize that the physicians prescribing medication in these studies received training on how to do “gold standard medical management,” including important behavioral components. So the real message is that, if you have a caring and competent physician prescribing buprenorphine who asks the right questions and makes the needed suggestions, adding on more behavioral interventions may not make a huge difference. All physicians in practice may not have these skills, though they are not difficult to learn. In methadone treatment, however, it is pretty clear that the medication plus standard drug counseling is better than simply giving medication alone.
 
Anne: What if people with OUDs have co-occurring psychiatric problems? I would think this is a big exception to the “no counseling benefit” finding – one that impacts many individuals.

Dr. Saxon: Very good point, and we don’t fully know the answer because individuals with severe psychiatric disorders are mostly screened out of such studies. However, patients with psychiatric disorders need psychotherapy and/or pharmacotherapy directed at their psychiatric disorders, not more behavioral interventions that address their addiction per se.
 
Anne: Some rehabs prefer Vivitrol to Suboxone, arguing that “they are equally effective head-to-head.” Is this true?

Dr. Saxon: Actually, there is far more evidence supporting the efficacy of Suboxone (and methadone) than injectable naltrexone or Vivitrol. Only one clinical trial done in Russia (which does not permit Suboxone or methadone) supports injectable naltrexone, and that’s the one on which the Food and Drug based its decision to approve Vivitrol for OUDs.

Right now, an ongoing study funded by the National Drug Abuse Treatment Clinical Trials Network is comparing the effectiveness of Suboxone versus Vivitrol for OUDs. Using naltrexone does require withdrawal off opioids for about a week before starting it, so it is more complicated than using the other maintenance medications in that way. However, if someone can make it through the withdrawal and wants to try Vivitrol, I wouldn’t have any qualms about it. But I would monitor the person carefully and be quick to switch to Suboxone if he or she isn’t doing well.

It’s also worth mentioning that the risk of overdose may be higher with naltrexone than with Suboxone or methadone if a client drop out or stop medications, but that’s a risk with any of the medications. Nevertheless, all patients should be warned.
 
Anne: The CEO of one rehab defended his decision to exclude Suboxone from their “abstinence-based facilities,” stating that their patients transfer to AA and NA in the community, and 12-step programs don’t see Suboxone or methadone users as abstinent. He said, “We don’t control how the recovery community sees the world. So our big focus has been on Vivitrol.”

Dr. Saxon: So their reasoning is that the AA groups fail to follow the precepts and stated policy of AA, which is to accept people who are on medications prescribed by physicians? The rehab program is not doing the medically correct thing by making their patients fit into AA groups that are run incorrectly. They should be out there trying to get AA groups to practice AA the right way. However, if they can get Vivitrol to work, wonderful, I’m all for it.
 
Anne: How do costs compare between the various forms of maintenance treatment, and how likely is insurance to cover them?

Dr. Saxon: Methadone costs between $300 and $400 per month, which includes medication, medical evaluation, counseling, and urine testing. The retail cost of Suboxone is about $300 to $400 per month, but physician and counseling fees are additional. Vivitrol is about $1000 per dose with one dose per month; physician and counseling fees are provided for an additional fee. Medicaid covers these treatments in many states, but exact coverage varies from state to state. Private insurance often covers them, but there are obviously variations from policy to policy. What I hear from physicians in private practice is that it can often be a huge hassle to get prior authorization.*

*Costs for primary care treatment [initial phase] at the adult residential facilities I visited for Inside Rehab five years ago ranged from $27,000 to about $55,000 for a 28- to 30-day stay.

 
Anne: The same rehab CEO I mentioned earlier stated that about 60 percent of people drop out of Suboxone treatment by the end of six months, and we need to be concerned. What do you think about this?

Dr. Saxon: I agree. I have a commentary coming out in the journal Addiction this year which makes the very same point. We need to improve our retention rates dramatically. However, saying that one treatment is suboptimal does not mean the other treatment (rehab) is necessarily better.

Let me just also say that I am not against rehab. I’ve simply had too many calls from families whose loved ones have gone through rehab multiple times and continue to use opioids. Rehab alone probably works for some, but when it doesn’t, we need to be quick to try medication.

Related Reading: The Buprenorphine Diversion Problem



Images Courtesy of Shutterstock/iStock

What Are Your Thoughts on this Topic?

We're Available 24/7

Call us toll free now!

1-888-341-7785